Loading organizations...
Lincoln Park Capital operates as a Chicago-based investment group and asset management firm. It specializes in opportunistic investing across diverse asset classes, including public and private companies, real estate, and fund-to-fund strategies. The firm employs fundamental analysis to invest in both growth and value stocks of small-cap and mid-cap companies, with a particular focus on the specialty finance sector.
The firm’s operational lineage extends back to 1999, when Mr. Jonathan Scheinfeld began founding investment funds. This deep experience in public and private markets, spanning over two decades, underpins the firm’s strategic approach to capital deployment. His insight was to create a flexible investment vehicle capable of identifying and capitalizing on opportunities across various market conditions.
Lincoln Park Capital primarily serves early and mid-stage private companies, alongside public companies throughout their development cycles. It provides not just capital, but also strategic guidance, especially within the specialty finance sector. The firm's long-term vision centers on leveraging its adaptable investment methodology to support enterprises and assets that offer significant growth potential in evolving markets.
Key people at Lincoln Park Capital.
Lincoln Park Capital was founded in 2010 by Joshua B Scheinfeld (Founder & Managing Member) and Richard C Vogel (Founder & President) and Robert A. Garcia (Founder & CFO) and Jonathan I. Cope (Founder & Managing Member).
Key people at Lincoln Park Capital.
Lincoln Park Capital was founded in 2010 by Joshua B Scheinfeld (Founder & Managing Member) and Richard C Vogel (Founder & President) and Robert A. Garcia (Founder & CFO) and Jonathan I. Cope (Founder & Managing Member).
Lincoln Park Capital has 3 tracked investments across 3 companies. The latest tracked deal is $25.0M Series A in Onchilles Pharma in November 2025.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Nov 7, 2025 | Onchilles Pharma | $25.0M Series A | — | Invivium Capital, Kennedy Lewis Investment Management, Lyzz Capital, University OF Chicago Medicine |
| Feb 7, 2019 | rMark Bio | $1.5M Seed | Lincoln Park Capital | M25, Mark Achler, SaaS Ventures |
| Feb 21, 2014 | PharmaCyte Biotech | $27.0M Other Equity | Lincoln Park Capital | — |